BCL11A and Schnyder corneal dystrophy: Both TDT and SCD patients infused with autologous CRISPR/Cas9-edited CD34+ HSPCs 9 targeting the GATA1 binding sequences at the erythroid-specific enhancer of BCL11A showed increased in fetal hemoglobin, transfusion independence, and elimination of vaso-occlusive episodes (in the SCD patients) [115].